Acute cholestatic hepatitis caused by amoxicillin/clavulanate
Carregando...
Citações na Scopus
10
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
BAISHIDENG PUBL GRP CO LTD
Autores
BERALDO, Daniel Oliveira
MELO, Joanderson Fernandes
BONFIM, Alexandre Vidal
TEIXEIRA, Andrei Alkmim
DUARTE, Andre Loyola
Citação
WORLD JOURNAL OF GASTROENTEROLOGY, v.19, n.46, p.8789-8792, 2013
Resumo
Amoxicillin/clavulanate is a synthetic penicillin that is currently commonly used, especially for the treatment of respiratory and cutaneous infections. In general, it is a well-tolerated oral antibiotic. However, amoxicillin/clavulanate can cause adverse effects, mainly cutaneous, gastrointestinal, hepatic and hematologic, in some cases. Presented here is a case report of a 63-year-old male patient who developed cholestatic hepatitis after recent use of amoxicillin/clavulanate. After 6 wk of prolonged use of the drug, he began to show signs of cholestatic icterus and developed severe hyperbilirubinemia (total bilirubin > 300 mg/L). Diagnostic investigation was conducted by ultrasonography of the upper abdomen, serum tests for infection history, laboratory screening of autoimmune diseases, nuclear magnetic resonance (NMR) of the abdomen with bile duct-NMR and transcutaneous liver biopsy guided by ultrasound. The duration of disease was approximately 4 mo, with complete resolution of symptoms and laboratory changes at the end of that time period. Specific treatment was not instituted, only a combination of anti-emetic (metoclopramide) and cholestyramine for pruritus.
Palavras-chave
Hepatology, Hepatitis, Amoxicillin/Clavulanate, Drug reactions, Hyperbilirubinemia
Referências
- BENICHOU C, 1990, J HEPATOL, V11, P272
- Brown SJ, 2002, SEMIN LIVER DIS, V22, P157, DOI 10.1055/s-2002-30103
- Cundiff J, 2007, AM J OTOLARYNG, V28, P28, DOI 10.1016/j.amjoto.2006.06.007
- Dandakis D, 2002, ANN GASTROENTOL H S1, V15, P85
- Farrokhseresht R, 2001, SEMJ, V2, P53
- Fontana RJ, 2005, DIGEST DIS SCI, V50, P1785, DOI 10.1007/s10620-005-2938-5
- Hautekeete ML, 1999, GASTROENTEROLOGY, V117, P1181, DOI 10.1016/S0016-5085(99)70404-X
- HAUTEKEETE ML, 1995, J HEPATOL, V22, P71, DOI 10.1016/0168-8278(95)80262-2
- Herrero-Herrero JI, 2010, J MED TOXICOL, V6, P420, DOI [10.1007/s13181-010-0019-4, DOI 10.1007/S13181-010-0019-4]]
- Kim Ju Seung, 2011, Korean J Hepatol, V17, P229, DOI 10.3350/kjhep.2011.17.3.229
- Maria VAJ, 1997, HEPATOLOGY, V26, P664, DOI 10.1002/hep.510260319
- RYLEY NG, 1995, J HEPATOL, V23, P278, DOI 10.1016/0168-8278(95)80471-4
- Salvo F, 2007, J ANTIMICROB CHEMOTH, V60, P121, DOI 10.1093/jac/dkm111
- Schey R, 2001, ANN PHARMACOTHER, V35, P1142
- SILVAIN C, 1992, DIGEST DIS SCI, V37, P150, DOI 10.1007/BF01308359
- Zaidi SA, 2003, AM J MED SCI, V325, P31, DOI 10.1097/00000441-200301000-00006